Heather Wakelee, MD

Heather Wakelee, MD, a professor of medicine at Stanford University Medical Center, discusses how physicians are treating patients with advanced lung cancer using targeted therapies, such as EGFR tyrosine kinase inhibitors (TKIs) in patients harboring an

mutations are targetable with EGFR TKIs, says Wakelee. Based on data from the&nbsp;

phase III FLAURA trial (NCT02296125), osimertinib

(Tagrisso) may be a better EGFR TKI option to start with because of the longer duration of response and improved overall survival compared with other EGFR TKIs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

-mutant lung cancers, Wakelee believes that osimertinib is a better treatment as it is more tolerated in patients. However, she warns that physicians should be mindful of potential cardiac and other toxicities.

story set the paradigm, leading to research in other driver mutations, such as&nbsp;

<< View more resources and information regarding EGFR-positive lung cancer

Videos

Heather Wakelee, MD, discusses how physicians are treating patients with advanced lung cancer using targeted therapies, such as EGFR tyrosine kinase inhibitors in patients harboring an&nbsp;EGFR&nbsp;mutation.

Treating Patients With EGFR-Mutant Lung Cancer With Targeted Therapies

Heather Wakelee, MD, associate professor of medicine at Stanford University Medical Center, discusses a recent trial looking at atezolizumab for NSCLC treatment.

An Overview of the BIRCH Trial Investigating Atezolizumab in NSCLC

Heather Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses the evolving role of bevacizumab (Avastin) in the treatment of patients with non&ndash;small cell lung cancer.

The Ongoing Research on Bevacizumab in Non-Small Cell Lung Cancer

Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University, discusses the rationale for immunotherapy in non-small cell lung cancer (NSCLC).

View the entire Special Report on Immunotherapy

Heather Wakelee, MD | Authors

Articles

Treating Patients With EGFR-Mutant Lung Cancer With Targeted Therapies

An Overview of the BIRCH Trial Investigating Atezolizumab in NSCLC

The Ongoing Research on Bevacizumab in Non-Small Cell Lung Cancer

The Rationale for Immunotherapy in NSCLC